ELUTIA INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ELUT in the last 7 days.
No SEC Form 4 filings for $ELUT in the last 30 days.
See all $ELUT insider activity →Elutia (ELUT) reported Q2 2026 earnings, highlighting $26M in new capital, strategic divestitures, and positive survey data for NXT-41x. The company aims to focus on reconstructive surgery market, valued at $1.5B. NXT-41x clearance is expected in 2027, with commercial launch in 2028. The company is funded through 2028.
ELUTIA INC. (ELUT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Elutia Completes SimpliDerm ® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch ● Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months ● Div
Elutia Inc. (NASDAQ: ELUT) said it completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million. Proceeds include $8 million at closing plus up to $3 million in contingent milestone payments. Elutia expects FDA clearance of its NXT-41x in H1 2027 and says funding supports operations through 2028 launch.
Recent ELUT coverage spans corporate actions, earnings and mergers & acquisitions.
The new financing strengthens the balance sheet and funds upcoming FDA clearance and product launch, likely supporting short-term upside.
The divestiture removes a revenue‑generating line but adds cash; short‑term price impact likely modestly negative as earnings will lose segment contribution.
Divestiture provides non-dilutive cash and refocuses the pipeline on NXT-41x, with FDA clearance expected in 1H 2027.
Forecast downgrade implies deteriorating fundamentals and higher downside risk versus prior consensus.
Funding runway is extended and partially contingent on FDA clearance milestones, making ELUT’s near-term risk and optionality more binary.
alphai scores every news story that mentions ELUT with an AI model for sentiment and relevance, and aggregates insider trades from ELUTIA INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elutia (ELUT) reported Q2 2026 earnings, highlighting $26M in new capital, strategic divestitures, and positive survey data for NXT-41x. The company aims to focus on reconstructive surgery market, valued at $1.5B. NXT-41x clearance is expected in 2027, with commercial launch in 2028. The company is funded through 2028.
2 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Elutia Completes SimpliDerm ® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch ● Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months ● Div
2 min readElutia Inc. (NASDAQ: ELUT) said it completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million. Proceeds include $8 million at closing plus up to $3 million in contingent milestone payments. Elutia expects FDA clearance of its NXT-41x in H1 2027 and says funding supports operations through 2028 launch.
2 min readElutia Inc. (NASDAQ:ELUT) shares fell after a covering analyst downgraded forecasts. The analyst cut 2026 revenue to $7.5m from $12m and raised expected losses to $0.63 per share from $0.60. Revenue is forecast to decline at a 62% annualized rate to 2026, worse than an industry aggregate 23% growth outlook.
3 min readElutia Inc. (NASDAQ:ELUT) said it secured up to $26M via a credit facility and SimpliDerm asset sale to fund operations through FDA clearance and launch of NXT-41x. Q2 net sales were $2.4M. It reported a $7.6M net loss and $19.9M cash at June 30, 2026. FDA decisions are expected in Q4 2026 (NXT-41) and H1 2027 (NXT-41x).
4 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track ● Funded through launch: secured up to $26 mil
6 min readElutia Inc. (Nasdaq: ELUT) said it secured a $15 million growth capital loan from Avenue Capital Group to fund development and commercialization of its NXT-41x antibiotic-eluting biomatrix for plastic and reconstructive surgery. Elutia received $10 million at closing, with a $5 million tranche contingent on FDA 510(k) clearance, expected in H1 2027.
4 min readElutia (Nasdaq: ELUT) reported Q2 2026 results and said it secured up to $26 million in non-equity funding for its NXT-41x program, including a $15 million credit facility and up to $11 million from a SimpliDerm divestiture. Q2 net sales were $2.4M, with a $7.6M net loss. The company cites a 96% surgeon interest survey and expects FDA decisions for NXT-41 in 4Q 2026 and NXT-41x in 1H 2027.
7 min readELUTIA INC. (ELUT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 tm2620864d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (i) NOT MATERIAL AND (ii) THE REGI
4 min readHealthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.
7 min read
